These medications work by regulating appetite, improving blood sugar control, and slowing gastric emptying, which helps reduce cravings and promote consistent fat loss
NHS England rolled out tirzepatide for weight management in cohorts after NICE TA1026 in December 2024: 3 Cohort 1 (from June 2025): adults with a body mass index (BMI) of 40 or higher and at least four of five weight-related conditions (type 2 diabetes, hypertension, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease)
Factors like body composition, baseline sleep quality, concurrent medications, and even your natural GABA receptor density all influence optimal dosing
The risk of complications may be compounded in those with comorbid AID
Or the ones with partially disclosed formulas